奥曲肽与帕瑞肽在分泌生长激素的垂体腺瘤中的体外头对头比较
在33例分泌生长激素的垂体腺瘤(GH瘤)原代培养中比较奥曲肽(OCT)与帕瑞肽(PAS)对生长激素(GH)分泌的抑制作用,并分析腺瘤生长抑素受体(SSTR)表达谱与疗效的关系。OCT(-36.8%)与PAS(-37.1%)对GH分泌的总体抑制效果相当;PAS对催乳素(PRL)过度分泌的抑制强于OCT(P < 0.01)。sst2 mRNA表达较低及sst2/sst5 mRNA比值较低的腺瘤对PAS反应更好。
要点
- OCT与PAS对GH分泌的总体抑制效果相当(-36.8% vs -37.1%)。
- PAS对PRL过度分泌的抑制强于OCT(P < 0.01)。
- sst2 mRNA低表达及sst2/sst5比值低的腺瘤对PAS反应更好。
核心结论
- 总体上,OCT与PAS在体外对GH分泌的抑制作用相当。
- sst2 mRNA表达较低及sst2/sst5 mRNA比值较低的腺瘤对PAS的反应优于OCT。
- GH瘤的SSTR评估可能成为肢端肥大症个体化SSA治疗的工具。
研究设计与样本
- 在33例GH瘤原代培养中检测OCT与PAS对GH(及PRL)分泌的影响,并在腺瘤样本中评估SSTR表达。
- 患者为荷兰鹿特丹Erasmus Medical Center收治的肢端肥大症患者。
- 干预为OCT与PAS处理72小时(10 nM)。
主要发现
- OCT对GH分泌的总体抑制为-36.8%,PAS为-37.1%,两者效果相当。
- 腺瘤分组:PAS+(PAS优于OCT)n = 6;PAS = OCT n = 22;OCT+(OCT优于PAS)n = 5。
- PAS+腺瘤的sst2 mRNA及sst2/sst5 mRNA比值低于其他组(P < 0.05)。
- PAS对PRL过度分泌的抑制强于OCT(P < 0.01)。
关键数值与推荐
- GH分泌抑制:OCT -36.8% vs PAS -37.1%。
- PAS+腺瘤sst2 mRNA及sst2/sst5 mRNA比值低于其他组,P < 0.05。
- PAS对PRL过度分泌的抑制强于OCT,P < 0.01。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: First-generation somatostatin analogs (SSAs), such as octreotide (OCT), are the first line medical therapy for acromegaly. Pasireotide (PAS), a newly developed SSA, has shown promising results in the treatment of acromegaly. OBJECTIVE: To compare the antisecretory effect of OCT and PAS in primary cultures of growth hormone (GH)-secreting pituitary adenomas (GH-omas). To correlate responses with the adenoma somatostatin receptor (SSTR) profile. DESIGN: The effect of OCT and PAS on GH (and PRL) secretion was tested in 33 GH-oma cultures. SSTR expression was evaluated in adenoma samples. SETTING AND PATIENTS: Patients with acromegaly referred to the Erasmus Medical Center (Rotterdam, The Netherlands). INTERVENTIONS: OCT and PAS treatment for 72 hours (10 nM). MAIN OUTCOME MEASURES: GH (and PRL) concentrations in cell culture media. SSTR expression in adenoma samples. RESULTS: The overall effect of OCT (-36.8%) and PAS (-37.1%) on GH secretion was superimposable. We identified three adenoma groups: PAS+ (PAS more effective than OCT), n = 6; PAS = OCT, n = 22; and OCT+ (OCT more effective than PAS), n = 5. PAS+ adenomas showed lower somatostatin receptor subtype (sst)2 messenger RNA (mRNA) and sst2/sst5 mRNA ratio, compared with the other groups (P < 0.05). PAS inhibited PRL hypersecretion more than OCT (P < 0.01). CONCLUSIONS: Overall, OCT and PAS equally reduced GH secretion in vitro. Adenomas with lower sst2 mRNA expression and lower sst2/sst5 mRNA ratio were better responders to PAS compared with OCT. SSTR evaluation in GH-omas may become a tool for tailored SSA treatment in acromegaly.
引用
- Gatto F, Feelders RA, Franck SE, et al. In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas. J Clin Endocrinol Metab. 2017. PMID: 28323931. doi:10.1210/jc.2017-00135
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。